3 results  1 of 1 

1 A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
Junsik Park, Kyung Jin Eoh, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Jung-Yun Lee
Yonsei Med J.2020;61(4):284-290.   Published online 2020 March 25     DOI: http://dx.doi.org/10.3349/ymj.2020.61.4.284
      
2 Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer
Ayaka Iura, Morihito Takita, Aiko Kawano, Kazuaki Imai, Katsuyuki Konnai, Ryo Onose, Hisamori Kato
J Gynecol Oncol.2018;29(5):e70.  Published online 2018 May 4     DOI: http://dx.doi.org/10.3802/jgo.2018.29.e70
      
3 External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
Jung-Yun Lee, Young Shin Chung, Kiyong Na, Hye Min Kim, Cheol Keun Park, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Hyun-Soo Kim
J Gynecol Oncol.2017;28(6):e73.  Published online 2017 July 24     DOI: http://dx.doi.org/10.3802/jgo.2017.28.e73
      

 1 of 1